NATCO Pharma has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.

This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International Limited (an affiliate of Teva Pharmaceut ical Industries Ltd) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.